Corvus Pharmaceuticals provided update on clinical trial of CPI-006 for patients with COVID-19
On Sept. 10, 2020, Corvus Pharmaceuticals announced updated data from its ongoing Phase 1 study investigating the potential…
-
-
Head-to-head study demonstrated equivalency and accuracy of COVID-19 rapid point-of-care tests, despite test sensitivity claims
On Sept. 9, 2020, BD (Becton, Dickinson) announced the results of a new research study that demonstrated performance…
-
Pfizer and BioNTech announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
-
BioNTech and Pfizer announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
-
iBio advanced COVID-19 LicKM-subunit vaccine candidate, IBIO-201
On Sept. 9, 2020, iBio announced that it had selected IBIO-201, its LicKMﾙ-ubunit vaccine, as its leading candidate…
-
AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary paused
On Sept. 9, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
-
RedHill Biopharma’s opaganib demonstrated complete inhibition of SARS-CoV-2
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…
-
Biotechnology | COVID-19 | Infectious Disease | Life Science History | Medicine | Non-Profit Research | Stem Cell | Therapeutics
California’s Stem Cell Agency and the Chan Zuckerberg Initiative partnered to create COVID-19 database
On Sept. 8, 2020, a new collaboration between the California Institute for Regenerative Medicine (CIRM) and the Chan…
-
Vaxartﾒs oral COVID-19 vaccine candidate induced potent systemic and mucosal immune responses in preclinical studies
On Sept. 8, 2020, Vaxart announced pre-publication of a manuscript titled ﾓPreclinical studies of a recombinant adenoviral mucosal…
-
DiaSorin Molecular received FDA clearance for the Simplexa Flu A/B & RSV Direct Gen II Assay
On Sept. 7, 2020, DiaSorin Molecular announced that it had received U.S. Food and Drug Administration (FDA) Clearance…
-
Johnson & Johnson announced COVID-19 investigational vaccine candidate prevents severe clinical disease in hamsters
On Sept. 3, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
-
ADMA Biologics launched COVID-19 ImmunoRank Neutralization MICRO-ELISA for detection of SARS-CoV-2
On Sept. 3, 2020, ADMA Biologics announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA…
-
COVID-19 vaccine study shows severe disease preventable in hamsters
On Sept. 3, 2020, Oregon Health & Science University (OHSU) announced that for the first time, early research…
-
Virginia Tech researchers began testing campus wastewater for COVID-19
On Sept. 3, 2020, a team of Virginia Tech researchers announced that they will begin testing wastewater at…
-
Roche received FDA Emergency Use Authorization for the cobas SARS-CoV-2 & influenza A/B test for use on cobas 6800/8800 systems
On Sept. 3, 2020, Roche announced that the cobas SARS-CoV-2 & Influenza A/B Test for use on the…
-
Aegis Sciences awarded $66 million NIH grant to rapidly expand COVID-19 test capacity
On Sept. 2, 2020, Aegis Sciences annunced that it had been selected to participate in the National Institutes…
-
Biotechnology | COVID-19 | NIH
PathGroup selected by NIH to become RADx program ‘mega-lab’ for COVID-19 testing
On Sept. 2, 2020, PathGroup announced the award of a funding grant from the National Institutes of Health…
-
Ceres received $65M NIH award to expand Nanotrapﾮ particle manufacturing capacity for COVID-19 testing
On Sept. 2, 2020, Ceres Nanosciences announced it had been awarded a contract from the National Institutes of…
-
NIH awarded MicroGEM $409 million to fast-track rapid, no-lab COVID-19 saliva test
On Sept. 2, 2020, MicroGEM announced it had been awarded up to $40.9 million by the National Institutes…
-
NIH-supported study to track prevalence and impact of SARS-CoV-2 among pregnant women in low- and middle-income countries
On Sept. 1, 2020, the National Institutes of Health announced that it had launched a study to track…
-
Titers of antibodies against SARS-CoV2 did not decline within four months
On Sept. 1, 2020, scientists at deCODE genetics in Iceland, a subsidiary of Amgen, published a study in…
-
MediciNova announced development progress on intranasal formulation of SARS-CoV-2 vaccine for COVID-19
On Sept. 1, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
-
Aegis Life launched to fight COVID-19 via DNA vaccines and therapeutics enabled by Fusogenix delivery technology
On Sept. 1, 2020, Entos Pharmaceuticals announce the launch of its San Diego-based spinout company Aegis Life, dedicated…
-
Development of COVID-19 vaccine AZD1222 expanded into U.S. Phase III clinical trial across all adult age groups
On Aug. 31, 2020, AstraZeneca announced that the COVID-19 vaccine AZD1222 expanded into U.S. Phase III clinical trial…
-
Vir Biotechnology and GSK started phase 2/3 study of COVID-19 antibody treatment
On Aug. 31, 2020, Vir Biotechnology and GlaxoSmithKline announced that the first patient was dosed in a phase…
-
T2 Biosystems received FDA Emergency Use Authorization for COVID-19 molecular diagnostic test
On Aug. 31, 2020, T2 Biosystems announced that the FDA had issued an Emergency Use Authorization (EUA) for…
-
Disease | NIH | Therapeutics
NIAID awarded BioCryst $44 million contract to advance development of galidesivir
On Aug. 31, 2020, BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) had…
-
Biotechnology | COVID-19 | Diagnostics | NIH
White House announced plan to deploy 150 million rapid tests in 2020
On Aug. 27, 2020, the U.S. Departments of Health and Human Services and the Department of and Defense…
-
AIM ImmunoTech decreased SARS-CoV-2 infectious viral yields by 90% using new in vitro model
On Aug. 27, 2020, AIM ImmunoTech announced that it had identified an effective in vitro model at The…
-
BioNTech and Fosun Pharma to potentially supply 10 Million doses of BNT162 mRNA-based vaccine candidate against SARS-CoV-2
On Aug. 27, 2020, Pfizer and Shanghai Fosun Pharmaceutical announced an intended collaboration to supply 10 million doses…
